CBR1 and hepatocellular carcinoma: However, the expression of the different AKRs and CBR1/3 in this tumor cell line is obviously not representative for the human liver: healthy human liver expressed much more CBR1 and less AKR1C3 mRNA than the neoplastic HepG2 cells (Fig. 10), matching previous data postulating that CBR1 is the predominant doxorubicin reductase in human liver (Kassner et al. 2008) and demonstrating that AKR1C3 is over-expressed in hepatocellular carcinoma (Zhu et al. 2021; Zhou et al. 2021; Zheng et al. 2022; Pan et al. 2022).